Stage 3 lung cancer means the cancer has spread beyond the lung itself into nearby lymph nodes or neighboring structures in the chest, but has not reached distant organs like the brain, bones, or liver. It sits between earlier stages (where the tumor is still confined to the lung) and stage 4 (where the cancer has spread to distant parts of the body). About 22% of lung cancers are diagnosed at this regional stage, and the five-year relative survival rate is 38.2%, according to national cancer registry data.
What “Regional Spread” Actually Means
In stage 3, the cancer has moved from the original tumor in the lung into the lymph nodes in the center of the chest (an area called the mediastinum) or into nearby tissues like the chest wall, the lining around the heart, or the major airways. The specific substage, 3A, 3B, or 3C, depends on how far that local spread has gone.
Stage 3A generally means the cancer has reached lymph nodes on the same side of the chest as the tumor, or has grown into adjacent structures but remains relatively contained. Stage 3B involves spread to lymph nodes on the opposite side of the chest or above the collarbone. Stage 3C describes larger tumors that have invaded nearby structures while also involving those more distant lymph nodes. The distinction matters because it directly affects whether surgery is an option.
How Stage 3 Is Diagnosed
If imaging like a CT or PET scan suggests the cancer has reached chest lymph nodes, doctors need to confirm it with a tissue sample. The standard way to do this is a procedure called endobronchial ultrasound, or EBUS. A thin scope is passed through the airway, and real-time ultrasound guides a small needle into suspicious lymph nodes to collect cells. A similar technique can be done through the esophagus. These procedures have largely replaced older surgical approaches for confirming lymph node involvement, though some patients still need a mediastinoscopy, a small surgery at the base of the neck.
Doctors typically sample lymph nodes in a specific order, starting with nodes farthest from the tumor and working inward. This helps map exactly how far the cancer has traveled, which determines the substage and shapes the treatment plan.
Symptoms at This Stage
Many people with stage 3 lung cancer have symptoms that go beyond a persistent cough or shortness of breath. As the tumor or enlarged lymph nodes press on structures in the chest, you might notice hoarseness that doesn’t go away, caused by pressure on the nerve that controls the vocal cords. Swelling in the face, neck, or arms can develop if the tumor compresses a major vein in the chest, a condition called superior vena cava syndrome. Chest pain, difficulty swallowing, and repeated lung infections are also common at this stage.
Whether Surgery Is Possible
One of the first questions after a stage 3 diagnosis is whether the tumor can be surgically removed. The two biggest factors are how many lymph node stations are involved and how deeply the tumor has invaded surrounding tissue.
A tumor that has reached only a single group of lymph nodes on the same side of the chest is generally considered resectable, meaning surgery is a realistic option. When cancer has spread to lymph nodes on the opposite side of the chest, or when enlarged nodes are bulky and matted together, the disease is typically considered unresectable. Cases that fall in between, like tumors involving multiple lymph node groups on the same side, are less clear-cut and usually require a multidisciplinary team to weigh the options.
Treatment for Resectable Stage 3
When surgery is feasible, it’s rarely the only treatment. Most patients receive a combination of therapies before and after the operation. Chemotherapy given before surgery (called neoadjuvant therapy) aims to shrink the tumor and kill cancer cells that may have spread microscopically. Increasingly, immunotherapy is added alongside that chemotherapy. After surgery, additional rounds of chemotherapy, immunotherapy, or targeted therapy may follow to reduce the chance of recurrence.
For patients whose tumors carry specific genetic mutations, targeted therapy after surgery can be particularly effective. These drugs zero in on the molecular changes driving the cancer’s growth rather than attacking all fast-dividing cells the way chemotherapy does.
Adding surgery to the treatment plan for stage 3A disease improves local control and delays progression, though studies have not consistently shown it extends overall survival compared to chemoradiation alone. The decision involves weighing surgical risks, lung function, and overall health.
Treatment for Unresectable Stage 3
When surgery isn’t an option, the standard approach is concurrent chemoradiation: chemotherapy and radiation delivered at the same time over several weeks. Giving both treatments together produces better survival than giving them one after the other, though it also causes more side effects, including fatigue, difficulty swallowing from irritation of the esophagus, and inflammation in the lungs.
The most significant advance in treating unresectable stage 3 lung cancer in recent years is the addition of immunotherapy after chemoradiation. In the landmark PACIFIC trial, patients who received up to 12 months of immunotherapy following chemoradiation lived a median of 47.5 months, compared to 29.1 months for those who received chemoradiation alone. At five years, 42.9% of patients in the immunotherapy group were still alive, versus 33.4% without it. The time before the cancer progressed also nearly tripled, from a median of 5.6 months to 16.9 months. This approach has become the standard of care for most patients with unresectable stage 3 disease whose cancer hasn’t worsened after initial chemoradiation.
For patients who can’t tolerate chemotherapy due to other health conditions, radiation alone is an option, though it is less effective. In some cases, radiation is used primarily to relieve symptoms like pain or airway obstruction rather than to try to cure the disease.
What the Survival Numbers Mean for You
The 38.2% five-year survival rate for regional-stage lung cancer is a population average drawn from patients diagnosed between 2016 and 2022. It includes people of all ages, health levels, and treatment plans. Your individual outlook depends on factors like the specific substage, how well you respond to initial treatment, your overall fitness, and whether the tumor has certain genetic features that can be targeted with newer drugs.
Survival rates have been steadily improving as immunotherapy and targeted therapies become standard parts of treatment. The PACIFIC trial results, for instance, reflect outcomes that weren’t available to patients diagnosed even a decade ago. Stage 3 is a serious diagnosis, but it is not stage 4, and for a meaningful portion of patients, long-term survival and even cure remain realistic goals.